View Older Stories View More Recent Stories

Sep 5, 2017 08:00AM Fibrocell to Present at Rodman & Renshaw 19th Annual Global Investment Conference and Global Genes’ 2017 RARE Patient Advocacy Summit
Aug 9, 2017 04:05PM Intrexon Announces Second Quarter and First Half 2017 Financial Results
Aug 9, 2017 08:00AM Fibrocell Reports Second Quarter 2017 Financial Results and Recent Highlights
Aug 3, 2017 08:00AM Fibrocell to Present at Canaccord Genuity 37th Annual Growth Conference
Aug 2, 2017 08:00AM Fibrocell to Host Conference Call and Webcast on Wednesday, August 9, 2017 to Discuss Second Quarter 2017 Financial Results and Recent Operational Highlights
Jun 12, 2017 08:01AM Fibrocell Science (FCSC) Announces Rare Pediatric Disease Designation from FDA for FCX-013 for Treatment of Localized Scleroderma
Jun 12, 2017 08:00AM Fibrocell Receives Rare Pediatric Disease Designation from FDA for FCX-013 for Treatment of Localized Scleroderma
Jun 8, 2017 08:07AM Fibrocell Science (FCSC) Completes Dosing of First Cohort in Phase 1/2 Clinical Trial of FCX-007 Gene Therapy for RDEB
Jun 8, 2017 08:00AM Fibrocell Completes Dosing of First Cohort in Phase 1/2 Clinical Trial of FCX-007 Gene Therapy for Treatment of Recessive Dystrophic Epidermolysis Bullosa
May 17, 2017 08:00AM Fibrocell to Present at Inaugural Cell & Gene Exchange 2017
May 10, 2017 04:05PM Intrexon Announces First Quarter 2017 Financial Results
May 10, 2017 08:00AM Fibrocell Reports First Quarter 2017 Financial Results and Recent Operational Highlights
May 9, 2017 09:14AM Fibrocell and Intrexon Announce Two Oral Presentations at the 20th Annual Meeting of the American Society of Gene & Cell Therapy
May 8, 2017 08:14AM Fibrocell Science (FCSC) Announces DSMB Recommends Continuation of Phase 1/2 Clinical Trial of FCX-007 for Treatment of RDEB
May 8, 2017 08:00AM Fibrocell Announces Data Safety Monitoring Board Recommends Continuation of Phase 1/2 Clinical Trial of FCX-007 for Treatment of Recessive Dystrophic Epidermolysis Bullosa
May 3, 2017 08:00AM Fibrocell to Host Conference Call and Webcast on Wednesday, May 10, 2017 to Discuss First Quarter 2017 Financial Results and Recent Operational Highlights
Apr 13, 2017 08:00AM Fibrocell to Present at 7th Annual World Orphan Drug Congress USA 2017 and 5th Annual Cell & Gene Therapy Investor Day
Mar 28, 2017 08:04AM Fibrocell Science (FCSC) Announces Compliance with NASDAQ Listing Requirements
Mar 28, 2017 08:00AM Fibrocell Regains Compliance with NASDAQ Listing Requirements
Mar 10, 2017 09:01AM Fibrocell Science (FCSC) Plans 1-for-3 Reverse Stock Split
Mar 10, 2017 09:00AM Fibrocell Announces One-for-Three Reverse Stock Split
Mar 9, 2017 08:00AM Fibrocell Reports 2016 Financial Results and Recent Operational Highlights
Mar 7, 2017 05:15PM Fibrocell to Host Conference Call and Webcast on Thursday, March 9, 2017 to Discuss 2016 Financial Results and Recent Operational Highlights
Mar 7, 2017 04:54PM Fibrocell Announces Convertible Preferred Stock Financing for $8.0 Million
Mar 1, 2017 05:10PM Intrexon Announces Fourth Quarter and Full Year 2016 Financial Results
Feb 23, 2017 08:00AM Fibrocell Announces Dosing of First Patient in Phase I/II Clinical Trial of FCX-007 Gene Therapy for Treatment of Recessive Dystrophic Epidermolysis Bullosa
Jan 5, 2017 08:04AM Fibrocell Science (FCSC) Receives FDA Fast Track Designation of FCX-007 for Treatment of RDEB
Jan 5, 2017 08:00AM Fibrocell Announces FDA Fast Track Designation of FCX-007 for Treatment of Recessive Dystrophic Epidermolysis Bullosa
Dec 19, 2016 08:00AM Fibrocell Announces Leadership Changes
Nov 10, 2016 08:39AM Fibrocell Science (FCSC) Names New Chief Medical Advisor
Nov 10, 2016 08:30AM Fibrocell Appoints Alfred T. Lane, MD, Chief Medical Advisor
Nov 9, 2016 04:05PM Intrexon Announces Third Quarter 2016 Financial Results
Nov 3, 2016 08:00AM Fibrocell Reports Third Quarter 2016 Financial Results and Recent Operational Highlights
Oct 31, 2016 04:01PM Fibrocell to Host Conference Call and Webcast on Thursday, November 3, 2016 to Discuss Third Quarter 2016 Financial Results and Recent Operational Highlights
Sep 29, 2016 08:00AM Fibrocell to Present at 2016 Cell & Gene Meeting on the Mesa
Sep 19, 2016 08:07AM Fibrocell Science (FCSC) Completes Enrollment in NC1+ Cohort of Phase I/II Clinical Trial of FCX-007 to Treat RDEB
Sep 19, 2016 08:00AM Fibrocell Completes Enrollment in NC1+ Cohort of Phase I/II Clinical Trial of FCX-007 for Treatment of Recessive Dystrophic Epidermolysis Bullosa
Sep 8, 2016 09:29AM Fibrocell Announces Closing of $18 Million Private Placement
Aug 9, 2016 04:05PM Intrexon Announces Second Quarter and First Half 2016 Financial Results
Aug 8, 2016 04:30PM Fibrocell Announces Proposed Public Offering of Common Stock and Warrants
Aug 4, 2016 08:01AM Fibrocell Reports Second Quarter 2016 Financial Results and Recent Operational Highlights
Jul 28, 2016 08:01AM Fibrocell to Host Conference Call and Webcast on Thursday, August 4, 2016 to Discuss Second Quarter 2016 Financial Results and Recent Operational Highlights
Jul 27, 2016 04:01PM Fibrocell Announces First Subjects Enrolled in Phase I/II Clinical Trial of FCX-007 for Treatment of Recessive Dystrophic Epidermolysis Bullosa
Jul 7, 2016 04:05PM Fibrocell to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference
Jun 29, 2016 04:31PM Fibrocell Science (FCSC) Updates on Azficel-T Wind-Down; Expects 'Significant' Cost Savings
Jun 29, 2016 04:30PM Fibrocell Expects Significant Cost Savings from Wind-Down of azficel-T Operations
Jun 13, 2016 08:04AM Fibrocell Science (FCSC) Commences Recruitment for FCX-007 Phase 1/2 as RDEB Treatment
Jun 13, 2016 08:00AM Fibrocell Announces Initiation of Patient Recruitment in Phase I/II Clinical Trial of FCX-007 for Treatment of Recessive Dystrophic Epidermolysis Bullosa
Jun 8, 2016 08:04AM Fibrocell Science (FCSC) Reports Azficel-T Phase 2 in Vocal Cord Scarring Missed Primary Endpoints
Jun 8, 2016 08:00AM Fibrocell Reports Phase II azficel-T Trial for Treatment of Vocal Cord Scarring Did Not Meet Primary Endpoints
View More Recent Stories View Older Stories